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ABSTRACT
Dehydroepiandrosterone (DHEA) concentration decreases with age, therefore, DHEA has been considered a hormone 
that reduces the symptoms associated with aging, so the usefulness of DHEA in premenopausal and postmenopausal 
women, and the options of hormone therapy have received a large amount of attention. The effectiveness of DHEA in the 
premenopausal women remains unclear, while in postmenopausal women with coexisting estrogens deficiency is con-
troversial. Despite many years of study, the use of DHEA is still controversial, especially regarding its effectiveness. The aim 
of present article was to evaluate DHEA specific effects on metabolic parameters, bone mineral density, insulin resistance 
as well as the therapeutic potential of DHEA in pre- and postmenopausal women using measures of sexual activity, cogni-
tion and well-being. The summary of this article is the position statement of expert group of the Polish Menopause and 
Andropause Society regarding the efficacy and safety of DHEA supplementation in women. We concluded, that currently 
available clinical trials and meta-analyses indicate that DHEA supplementation is effective in women with adrenal insuf-
ficiency and chronically treated with exogenous glucocorticoids, postmenopausal women with low bone mineral density 
and/or osteoporosis, premenopausal women with sexual disorders and low libido, and in women with vulvovaginal atrophy 
due to menopause or genitourinary syndrome of menopause. Currently available clinical trials also suggest that DHEA 
supplementation is probably effective in postmenopausal women with hypoactive sexual disorders, infertile women with 
diminished ovarian reserve, women suffering from depression and anxiety, and women with obesity and insulin resistance. 
No serious adverse effects have been reported.
Key words: dehydroepiandrosterone; perimenopause; menopause
Ginekologia Polska 2020; 91, 9: 554–562
INTRODUCTION
Dehydroepiandrosterone (DHEA) represents the most 
abundant steroid hormone in humans. DHEA concentra-
tion gradually decreases with age reaching the lowest levels 
about the time when the incidence of many diseases increas-
es. Therefore, DHEA has been considered a hormone that slows 
down or prevents aging, or at least reduces the symptoms 
associated with aging, therefore the usefulness of DHEA in 
perimenopausal and menopausal women, and the options to 
hormone therapy have received a large amount of attention. 
However, not all aspects of physiology, pathophysiol-
ogy, mechanism of actions, clinical relevance and safety 
of DHEA supplementation in women have been known 
to date. The effectiveness of DHEA in the premenopausal 
women remains unclear, while in postmenopausal women 
many symptoms are caused by both estrogens and DHEA 
deficiency. Therefore, it is difficult to clearly distinguish be-
tween menopause and adrenopause. Despite many years 
of study, the use of DHEA is still controversial, especially 
regarding its effectiveness.
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The aim of present article was to evaluate DHEA specific 
effects on metabolic parameters, bone mineral density, 
insulin resistance as well as the therapeutic potential of 
DHEA in pre- and postmenopausal females using measures 
of sexuality, cognition and well-being. The summary of this 
article is the position statement of expert group of the Polish 
Menopause and Andropause Society regarding the efficacy 
and safety of DHEA supplementation in women.
DHEA IN HUMAN PHYSIOLOGY
Dehydroepiandrosterone (DHEA) is an endogenous an-
drogen produced in zona reticularis of adrenal cortex (30%), 
thecal cells in ovary (20%), and from peripheral conversion 
of DHEAS (30%). 
In peripheral tissues DHEA is converted to more ac-
tive androgens and estrogens: estrone and testosterone 
and later to estradiol and dihydrotestosterone (DHT) re-
spectively. The contribution is remarkable, since in post-
menopausal women 40–75% of testosterone and 90% of 
estrogens are derived from adrenal androgens [1]. DHEA-S 
serves as a circulating reservoir of DHEA. DHEA can be re-
versely transformed in many tissues by sulphatases from its 
sulphate (DHEA-S). Together with its sulphate, DHEA is the 
most concentrated hormone and the most abundant ster-
oid in peripheral blood, thus it became clear that it is more 
than just an intermediate in steroid hormone synthesis. Se-
rum DHEA concentrations range from 0.2 to 0.9 mcg/dL (7 to 
31 nmol/L). Due to its remarkable and gradual decrease that 
occurs with aging, DHEA was considered as an anti-aging 
elixir and concept of dietary supplementation of DHEA was 
promoted and administration was introduced in 1980s [2]. 
As primary effects improvement in sexual function, well-be-
ing, metabolic parameters, immune response, and cognition 
were suggested. Noteworthy many initial studies regarding 
anti-aging properties and mechanisms of DHEA were con-
ducted on rodents that naturally do not secrete DHEA from 
adrenal glands, thus may be irrelevant [3]. DHEA also plays 
an important role in reproductive endocrinology. As other 
androgens, DHEA is important in follicular steroidogenesis 
and oogenesis in ovary. Described effects on ovarian fol-
liculogenesis includes upregulation of insulin-like growth 
factor-1 (IGF-1) [4], sensitization to gonadotropins and re-
duction of follicular arrest [5].
Secretion of DHEA is stimulated by ACTH from pituitary 
gland; however, levels of DHEA-S are not linked directly to 
ACTH due to long plasma half-life time and high concen-
tration of the sulphate. The hydrophilic DHEA-S is secreted 
mainly by adrenal glands and is a major circulating and most 
stable form of DHEA that can easily be interconverted in tar-
get tissues. Metabolism of DHEA is modulated by binding to 
plasma proteins, since SHBG have low affinity to DHEA and 
no affinity to DHEA-S. Albumins weakly binds DHEA but have 
high affinity to DHEA-S and increases its half-life time [6].
Physiologically, their production clearly increases 
in children between 6–8 years of age, which is called 
adrenarche. These hormones in the child’s target tissues 
are converted to steroids with more activity. The place 
of conversion is, inter alia, the skin. Pubic hair appears 
apocrine sweat glands begin to function, and sebaceous 
gland secretion increases. At this time, slight acceleration 
is also observed in bone growth and maturation. DHEA 
and DHEA-S levels have been shown to depend on nutri-
tional status. Obese children have higher levels of DHEA-S 
and earlier achieve adrenarche than lean children. Some 
research suggests that adrenal androgens directly or 
after peripheral conversion to estrogen modulate hy-
pothalamic activity influencing the gonadarche. DHEA 
and DHEA-S concentrations increase gradually to the 
third decades of life. Peak secretion of these hormones 
falls for ages between 20 and 30 years old. Levels since 
then DHEA and DHEA-S in the blood gradually decrease 
to reach 20% of its maximum value in its 70s, up to a fall 
to 5% at the age of 85–90 [7]. Humans and primates are 
unique in their capacity to produce large amounts of 
adrenal steroids.
In postmenopausal women ovarian production of 
DHEA is ceased in contrast to testosterone that is still pro-
duced by postmenopausal ovaries for many years [8]. Di-
verse conditions influence the DHEA(S) activity. DHEA and 
DHEA-S can be suppressed in many pathological conditions 
including acute stress, severe chronic systemic diseases, 
anorexia nervosa, ACTH-independent Cushing’s syndrome 
and chronic medication with anti-inflammatory doses of 
glucocorticoids (GCS). Higher levels were described in hy-
perprolactinemia [3].
DHEA exerts its primary effects through its estrogenic 
and androgenic derivatives since a unique DHEA receptor 
is not known. However, DHEA exhibits a weak antagonist 
effect on the androgen receptor (AR) [9]. It was described 
that DHEA plays a role as a low-affinity ligand for hepatic 
nuclear receptors, such as the pregnant X receptor, the 
constitutive androstane receptor, and estrogen receptors 
α/β (ERα/ERβ) as well as G protein-coupled ER (GPER1) [1]. 
Moreover, DHEA may act in brain as an stimulatory neu-
romodulator by blocking the action of the gamma-am-
inobutyric acid type A (GABA) receptor, as well as, acti-
vating the N-methyl-D-aspartate (NMDA) receptor and 
the σ-subtype 1 receptor, thus having anti-depressive 
potential. Furthermore, DHEA can play a role in endothelial 
proliferation and angiogenesis through membrane-bound 
G-coupled receptor that has been described on vascular 
endothelial cells [3].
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SUPPLEMENTATION OF DHEA AS 
A HORMONE REPLACEMENT THERAPY IN 
PREMENOPAUSAL AND POSTMENOPAUSAL 
WOMEN
Postmenopausal women present sharp drop in estra-
diol level and rapid rise of FSH. In elderly males slow but 
continuous, age-dependent decline of testosterone level 
is observed. The decrease is more pronounced for free tes-
tosterone as a result of the age-associated increase of the 
levels of sex hormone binding globulin (SHBG). Moreover, 
the circadian rhythm of testosterone secretion is lost in 
elderly men. The age-associated decrease of DHEA is the 
most important and ubiquitous decrease of all hormones in 
all men and women [10]. In contrast to estradiol breakdown, 
androgens are secreted for many years after menopause. 
Interestingly some menopausal women, e.g., after bilateral 
oophorectomy or premature ovarian failure, experience 
concomitant deficiency of androgens, thus could clearly 
benefit from DHEA supplementation [11].  
Osteoporosis, metabolic health,  
and muscular strength
DHEA is the precursor for at least 70% of androgens in 
elderly women, and a major origin of estrogens in males and 
postmenopausal females. Therefore, it has been suggested 
that the drop in DHEA level with aging leads to physiological 
changes that are dependent on steroid hormones, such as 
the loss of bone density and muscular mass. 
A small number of randomized controlled trials 
have assessed changes in bone mineral density (BMD) 
in older females on DHEA replacement therapy at doses 
of 25–100 mg/d. In a randomized controlled trial, the ef-
fect of 12-month supplementation with DHEA on BMD 
in 70 women, aged 60-88 years with low serum DHEAS 
concentration levels at baseline was investigated [12]. The 
intervention compared oral DHEA 50 mg/d with placebo for 
12 months. Intent-to-treat analyses showed trends towards 
increase of BMD with DHEA versus placebo at the total hip 
(1.0%), trochanter (1.2%), shaft (1.2%), and lumbar spine 
(2.2%). Also, modest effects of DHEA supplementation on 
bone density in postmenopausal women was observed 
when treatment time exceed 52 weeks [3].
A recent systematic review with meta-analysis of 
randomized placebo-controlled studies of DHEA supple-
mentation of BMD in healthy women revealed, that hip 
and trochanter BMD increased remarkably above control 
group in individuals, who took DHEA supplementation 
[13]. During DHEA therapy, serum osteocalcin also in-
creases (from 1.16 to 2.44 μg/L), which is a marker of bone 
formation [14].
The aging process in women is associated with changes 
in muscle, that can lead to sarcopenia, and about 20% of 
patients with sarcopenia are functionally disabled. An im-
portant reason for this phenomenon is a marked decline in 
serum sex steroids – estradiol and DHEA. In postmenopausal 
women, DHEA becomes the predominant sex hormone, 
however the relationship among, DHEA, and mass of mus-
cles or strength in women after the menopause has not 
been documented. 
Therefore, the relation between the level of intramuscu-
lar steroid hormones and muscle characteristics in menstru-
ating women was investigated [15]. The authors measured 
isometric skeletal muscle strength, knee extension strength, 
and explosive lower body muscle power. They conclud-
ed that intramuscular estradiol, testosterone, and DHEA 
are proved significant, independent predictor factors of 
strength and power that explains 59–64% of the difference 
in knee extension strength and 80–83% of the difference of 
vertical jumping height in women. These results suggests 
that intramuscular sex hormones are related with strength 
and power level in female muscles.
In most recent study [16] the relationship between sex 
steroids (DHEA, testosterone and estradiol) muscle mass, 
and muscle strength in postmenopausal women were in-
vestigated. Women classified within the lowest DHEA and 
free testosterone tertile had lower muscle strength in com-
parison to those placed in the highest tertile (adjusted OR 
for DHEA 1.42; 95% CI 1.02–1.99), however, estradiol was 
not related to muscle strength. 
The accumulation of abdominal fat increases with age, 
and is associated with insulin resistance, diabetes, and ath-
erosclerosis. Hormonal changes (low DHEA levels) that occur 
with aging may contribute to the increase in abdominal fat. 
Administration of DHEA to reduce visceral fat accumulation 
in rats, and has a protective effect against insulin resistance 
and the decrease in insulin responsiveness. A possible expla-
nation for these findings is that DHEA is an alpha activator 
of peroxisome proliferator activated receptor α (PPARα), 
what is associated with favor increasing of fat oxidation and 
reducing fat deposition. 
The influence of DHEA supplementation of insulin me-
tabolism was also investigated in women. In randomized, 
double-blind, placebo-controlled trial conducted in 
28 women with age-related decrease in DHEA level, par-
ticipants received 50 mg/d for 6 months [17]. DHEA therapy 
results in significant decreasing in visceral and fat and sub-
cutaneous fat area. Also, the insulin levels decreased, and 
insulin sensitivity increased during the OGTT after DHEA 
therapy. So, authors concluded, that DHEA replacement 
therapy could play a role in prevention and management of 
the metabolic syndrome associated with abdominal obesity 
in women. Despite these results, there are no sufficient data 
in terms of influence of DHEA supplementation on insulin 
sensitivity as well as lipid profiles in women [3].
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Depression, anxiety, cognitive function  
and mood improvement
Currently, many data indicate, that DHEA modulate 
many neurobiological actions and there are evidences show-
ing that DHEA concentrations are inversely correlated with 
ratings of depressed mood [18]. DHEA as well as gluco-
corticoids take a part in regulation of many physiological 
mechanisms and play an important role in regulation of 
affect and its dysregulation. DHEA levels remarkably de-
crease throughout adulthood but an increase in circulating 
cortisol level with advanced age has been proved in human. 
Therefore, it can be interesting to consider the fraction of 
both hormones in addition to their absolute levels of con-
centration. Lower DHEA to cortisol ratio may impact many 
physiological functions, including learning, memory, and is 
associated with greater cognitive impairment. It has been 
recently revealed that DHEA treatments improve cognitive 
deficits and depressive like behaviors in animals by promot-
ing neurogenesis in the hippocampus [19].
In patients with posttraumatic stress disorder (PTSD), 
which is classified as the anxiety disorder, elevated DHEA 
concentration was identified, and researchers have sug-
gested, that DHEA may have a role in resilience and in proper 
adaptation to stressors [20].
Majority of studies have reported lowered serum con-
centration levels of DHEA in subjects with poor life quality, 
satisfaction and psychosocial stress. Higher plasma and se-
rum concentrations of DHEAS have also been associated with 
greater amount, frequency, and enjoyment of leisure activi-
ties and psychological profiles associated with health [21]. 
Clinical trials of DHEA treatment for depression con-
stantly suggest beneficial consequences. Randomized 
control trials showed that application of DHEA used alone 
or as an antidepressant adjunct in unresponsive patients 
with depression, has significant antidepressant effects (as 
shown by improvements in Hamilton Depression Ratings 
and Symptom Checklist) in some of them. In most studies, 
authors stated that baseline serum DHEA concentrations 
did not predict antidepressant response, responders to 
DHEA reached higher serum DHEA concentrations follow-
ing treatment and antidepressant effects were directly 
correlated with variation in DHEA levels [22, 23]. However, 
recent data suggest that higher circulating DHEA(S) levels 
can predict SSRI-associated remission in major depression 
[24]. It is obvious that, more trials will be necessary to es-
tablish the place of DHEA supplementation in therapy of 
patients with depression, and to compare DHEA to standard 
antidepressants.
Libido and sexual satisfaction
Sexual desire and libido in women are affected by endo-
crine factors. Adrenal androgens are necessary for normal 
sexual function, while disorders characterized by androgen 
deficiency are associated with a low frequency of sexual 
activity. 
Although testosterone plasma levels do not correlate 
directly with sexual function in cross-sectional and longitu-
dinal studies, they have the main role in sexual desire [25], 
On the other hand, it is suggested, that a poor DHEA level 
negatively correlates with sexual function in women before 
and after menopause [26]. 
DHEA supplementation has been recognized for its 
beneficial effect on sexual function but still the effects of 
DHEA therapy on sexuality in postmenopausal women are 
controversial [27], what is mainly associated with dose of 
DHEA and treatment time.
In most recent study, authors reported the influence of 
DHEA supplementation in dose of 10 mg daily on sexual 
function, frequency of sexual intercourse, and quality of rela-
tionship early after menopause [28]. Efficacy was evaluated 
using the McCoy Female Sexuality Questionnaire during 
12 months of treatment. DHEA supplementation related to 
improvement in sexual function, and significant growth in 
the numbers of sexual intercourses. 
The results of DHEA administration on sexual function 
was also investigated in premenopausal women. This obser-
vational study [29] investigated the effect of DHEA in dose 
25 mg three times a day on the Female Sexual Function 
Index (FSFI) in women with mean age 41 years. The FSFI 
score for the treated group raised by 7%, domain scores 
for desire raised by 17% and by 12% for arousal, while no 
difference in domain scores for orgasm or satisfaction were 
proved. Women starting in the lowest quartile of FSFI score, 
experienced 34% growth in total FSFI score during treat-
ment with DHEA. Among participants of a trial, improve-
ments in domain categories were shown for desire (40%), 
arousal (46%), lubrication (33%), orgasm (54%), and sexual 
satisfaction (24%). This study implies that administration of 
DHEA improved sexual function in premenopausal women 
from low baseline FSFI scores group.
Androgen replacement in unselected postmenopausal 
women has been administrated for decades as an off-label 
treatment. Recently a global consensus on testosterone 
replacement for women was formulated [30]. The statement 
does not support the systemic and local use of DHEA for hy-
poactive sexual desire disorder (HSDD) in postmenopausal 
women with proper adrenal function. While, testosterone 
treatment, in doses that are in normal range of the physi-
ological testosterone concentrations for premenopausal 
women, results in a beneficial effect on sexual function. 
Study included increases, above the effects of placebo/com-
parator therapy, of an average of one satisfying sexual event 
per month, and increases in the subdomains of sexual desire, 
arousal, orgasmic function, pleasure, and sexual responsive-
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ness. On the other hand, a reduction in sexual concerns 
including sexual distress was observed.
More adequately powered, double-blind RCTs, with no 
selection bias and with consistent reporting and analysis 
of standardized results, are required to comprehensively 
document the benefits and risks of DHEA and testosterone 
supplementation in women.
Cosmetic dermatology
DHEA can also be used in cosmetic dermatology. It 
has been shown to act on the sebaceous glands, increases 
sebum production in postmenopausal women, and thus 
prevents the skin from drying out. This effect is due to pres-
ence in these cells, the steroidogenesis enzymes necessary 
for catalyzing the transformation reaction of DHEA to DHT, 
which is main stimulator of sebaceous gland activity [31]. 
In addition, DHEA could improve skin hydration reduction 
of its pigmentation [32].
SUPPLEMENTATION OF DHEA IN WOMEN 
WITH ADRENAL INSUFFICIENCY AND 
CHRONICALLY TREATED WITH EXOGENOUS 
GLUCOCORTICOIDS
Highest beneficial effect of DHEA supplementation 
was reported in individuals with virtually complete 
DHEA deficiency that occurs in adrenal insufficiency [11]. 
Primary or iatrogenic adrenal insufficiency, despite 
supplementation of glucocorticoids (GKS), leads to de-
creased quality of life (QoL) when compared to healthy 
population [33]. DHEA supplementation has been stud-
ied as an accessory treatment to conventional adrenal 
replacement therapy with glucocorticoids and miner-
alocorticoids. The exact physiological roles of DHEA still 
remains not fully elucidated and the routine therapy in 
individuals with adrenal insufficiency is still controver-
sial. Some papers reported significant improvements of 
mood, well-being, sexual thoughts, libido, interest and 
satisfaction following DHEA replacement particularly 
in females [11, 34]. Other analysis of DHEA adminis-
tration in women with primary and secondary type of 
adrenal insufficiency have resulted in inconsistent and 
unreproducible data [35]. According to recent recom-
mendations, supplementation of DHEA is indicated in 
hypo-adrenal women with low libido, depressive symp-
toms, low energy levels or impaired sense of well-being 
despite optimized glucocorticoid and mineralocorticoid 
replacement [36].
In women with systemic lupus erythematosus, treated 
with high, that is anti-inflammatory doses of corticoids 
DHEA reduced disease activity and had an antiosteoporo-
tic effect. One study suggested also benefits for cognitive 
function in such patients [37]. 
SUPPLEMENTATION OF DHEA IN WOMEN 
WITH VULVOVAGINAL ATROPHY
Efficacy and safety of DHEA were also investigated in 
women with vulvovaginal atrophy due to menopause, 
also called genitourinary syndrome of menopause (GSM), 
especially in women suffering from moderate to severe 
dyspareunia or pain at sexual activity.
In a prospective, double-blind, and placebo-controlled 
clinical trials with randomization, the effect of intravaginal 
0.50% DHEA (6.5 mg per day) was assessed on four copri-
mary objectives, i.e.,  percentage of parabasal cells, per-
centage or superficial cells, level of vaginal pH, and pain at 
sexual activity (moderate and severe dyspareunia) identified 
by the women as most troublesome vulvovaginal atrophy 
symptom. After intravaginal administration of 0.50% DHEA 
for a period of 12 weeks, the fraction of parabasal cells was 
decreased by 27.7%, whereas the percentage of superficial 
cells were increased by 8.44%, vaginal pH was reduced by 
0.66 pH, and the pain at sexual intercourse decreased by 
1.42 severity score unit from the baseline. On the other hand, 
moderate or severe vaginal dryness, that was present in 
84.0% of women, have improved at 12 weeks by 1.44 severity 
score unit in comparison to baseline. At gynecological ex-
amination vaginal secretions, epithelial integrity, epithelial 
surface thickness, as well as, color were all improved [38].
The clinical benefits of DHEA therapy demonstrated in 
12-week studies, were also confirmed in 52-week study [39]. 
After 52 weeks of treatment, a significant betterment was 
seen in comparison to the baseline in parameters such as 
a decrease in the fraction of parabasal cells, a growth in 
the fraction of superficial cells, and a decrease in vaginal 
pH, as well as the volume of vaginal discharge, and vagi-
nal epithelial integrity, thickness and color. In women who 
suffer from moderate to severe dyspareunia as the most 
bothersome symptom of GSM, and who met the inclusion 
criteria of postmenopausal vaginal atrophy, the pain severity 
score was decreased by 46.7% during 12 weeks period, and 
further by 19.4% between 12 and 52 weeks, finale reaching 
the level of 33.9% of the baseline at week 52. In women that 
suffer from moderate to severe dyspareunia and considered 
vaginal dryness or vaginal irritation/itching as the most 
bothersome symptom of atrophy, the pain severity score re-
duced from 2.42 ± 0.07 at baseline to 0.77 ± 0.12 at week 52. 
Moreover, in females with moderate and severe vaginal 
dryness or vaginal irritation/itching, the severity of each of 
the symptoms after 52 weeks of administrating prasterone 
decreased also significantly. 
SUPPLEMENTATION OF DHEA FOR FERTILITY 
IMPROVEMENT
Diminished ovarian reserve (DOR) is a common cause of 
otherwise unexplained infertility, as well as, early ovarian hor-
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monal insufficiency and related endocrinopathies. Recently 
published meta-analysis that included 14 studies shows that 
individuals with premature ovarian insufficiency (POI) have 
lower concentration levels of androgens in comparison with 
healthy controls: DHEAS, testosterone and androstendione 
[40]. Others estimated that suboptimal DHEAS concentra-
tions are quite common and were found in 65% of women 
with diminished ovarian reserve DOR [41]. Androgen levels 
are lower in POI than in women with regular cycles [42]. 
Autoimmunological disorders can have a role in deregulated 
function of DHEA on DOR. Occurrence of the anti-thyroid 
antibodies in women with POI correlated with deeper drop 
of DHEAS. Treatment with DHEA caused decrease in thy-
roid peroxidase autoantibodies levels [43]. In a small group 
consisting of 25 patients with POF high proportion (44% 
vs. 4%) of autoantibodies was found. Moreover, occurrence 
of autoimmunity was associated with higher DHEAS level 
decrease [44].
Supplementation of DHEA in IVF cycles
The DOR is a leading challenge for artificial reproductive 
technologies (ART), since growing incidence and significant 
decrease in the effectiveness of stimulation and outcome of 
in-vitro fertilization (IVF). It can be explained by decreased 
ovarian reserve and reduced oocyte quality. Although, 
ESHRE recommendations do not support any therapeutic 
modality in premature ovarian insufficiency promoting oo-
cyte donation in such cases. Moreover, it is indicated that 
androgen administration has poor evidence in infertility 
treatment [45]. Up to date, many attempts were done to 
improve the effectivity of therapy in infertile DOR women. 
Supplementation with DHEA is one of the solutions to the 
problem. A recent meta-analysis proved that the rates of 
clinical pregnancy (CPR) were improved significantly when 
DHEA pre-treatment was implemented (OR = 1.47, 95% 
CI: 1.09–1.99). No differences in the number of oocytes 
retrieved, the cancellation rate, and the miscarriage rate 
was reported [46]. Other meta-analysis reported supple-
mentation with DHEA as a therapy that improve IVF results 
in patients with DOR. However, randomized controlled trials 
did not give a prove for the performance of DHEA therapy, 
one prospective randomized trial revealed that DHEA may 
increase potential for fertility in women without DOR [47]. 
Since females with normal ovarian reserve supplemented 
with DHEA had a significantly better live birth rate and 
a lower miscarriage rate [48], it has been even indicated 
that all women aged above 35 years may be treated with 
DHEA to diminish the abortion rate and increase treatment 
effectiveness [49].
The physiological processes underlying advantageous 
activity of DHEA occurred to be still not fully determined. 
Supplementation with DHEA rise the number of top-quality 
embryos, transfers and fertilization rate compared with 
placebo group. Moreover, supplementation was shown 
to decrease DNA damage and rate of apoptosis, increase 
the mitochondrial fraction, and dehydrogenase activity 
in mitochondria of cumulus oophorus [50]. DHEA admin-
istration caused that higher embryo score is associated 
by changes in follicular fluid constitution that includes 
variation in bone morphogenic protein-15 (BMP-15) [51]. 
Other authors reported that DHEA advantageous effect on 
gonad is caused by reduced concentration of senescence 
marker: senescence-associated β-galactosidase (SA-β-gal) 
in cumulus oophorus and in granulosa cells [52]. Adminis-
tration of DHEA increases the level of androgen receptor 
(AR) and follicle-stimulating hormone receptor (FSHR) in 
granulosa cells. Moreover, higher increase was associated 
with improved results of stimulation [53]. It is known that 
DHEA, as well as, its downstream metabolites can act by 
modulation of immune response. The supplementation 
could also increase the Th1 immune response and change 
the balance of the Th1/Th2 ratio. Studies on animal model 
also indicated some mechanisms. DHEA administration may 
increase T lymphocyte infiltration on murine model, causing 
a decrease in the CD4+ T lymphocyte population, an in-
crease of the CD8+ T lymphocyte number. Therefore, change 
in of balance between CD4+/CD8+ T cells take a place [54].
Supplementation of DHEA in natural cycles
Treatment with DHEA has been applied in infertile fe-
males with low ovarian reserve who try to conceive spon-
taneously. One of first case series by Mamas and Mamas 
described five females with POI supplemented with DHEA. 
The treatment caused decrease in level of FSH and spon-
taneous pregnancy in all reported patients that occurred 
in 1-6 months from start of treatment [55]. DHEA was evi-
denced to significantly upregulates AMH in patients with 
DOR. Advantageous outcomes were reported for antral fol-
licle count (AFC), estradiol, inhibin B and FSH concentrations 
[56–58]. Trials on patients pre-treated with DHEA, because 
of low ovarian response, reported remarkably high num-
ber of spontaneous pregnancies and ongoing pregnancies 
(21.05% and 13.15% respectively). Recent paper show that 
2 in 20 supplemented patients conceived spontaneously in 
DHEA group [59]. Many small series of cases advocating for 
implementation of DHEA supplementation in infertile DOR 
patients that refuses oocyte donation in IVF treatment have 
been published so far [60]. 
In the animal model supplementation of DHEA reversed 
the DOR phenotype and reduced atresia rate of the follicles 
in rats. After administration animals had increased number 
of primordial, primary, and growing follicles in comparison 
to untreated group. However, androgen supplementation 
did not reverse the phenotype completely and the number 
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of follicles was still reduced in comparison to control rats 
without DOR [61].
Studies on rat model of DOR showed that there is a win-
dow for DHEA dose. To high dosage of DHEA did not improve 
the ovarian reserve and pregnancy outcome, but rather 
induce PCOs-like morphology of gonads and impair fertility. 
This fact indicates the necessity of personalization of the 
treatment. Tailoring the dose of DHEA and proper selection 
of patients that will have improvement thanks to the therapy 
would increase the effectiveness [62]. Therefore, assessment 
of DHEA-S level and supplementation of DHEA selectively 
in low-DHEAS group seems to be reasonable and proper 
treatment strategy [60].
SIDE EFFECTS OF DHEA SUPPLEMENTATION 
AND CONTRAINDICATIONS
Common androgenic side effects of DHEA replacement 
have been reported so far: hirsutism, acne, greasy skin, itch-
ing of the skin scalp, abundant vaginal discharge, increased 
apocrine secretion of sweat and related odor. Some studies 
reported no such side effects. The side effects were infre-
quent, mild and well-tolerated. No serious adverse effects 
have been ever reported [35, 63, 64].
Prior to initiating supplementation with DHEA a com-
plete family and personal medical record should be ob-
tained. Careful gynecological and breast examination 
should be done periodically. Contraindications and possible 
benefit-risk profile should be considered before treatment 
and during follow-up. Temporal and persistent contraindi-
cations for DHEA supplementation that should be consider 
[63] includes: 
•	 hypersensitivity to the substances contained in the for-
mulation,
•	 non-diagnosed vaginal bleeding, untreated endometrial 
hyperplasia
•	 diagnosed breast cancer, history or suspicion of breast 
cancer
•	 estrogen-dependent malignancy (diagnosed or sus-
pected)
•	 pregnancy or breastfeeding
•	 acute liver disease, elevated liver enzymes, kidney failure
•	 previously or currently diagnosed venous thrombo-
embolism, known susceptibility to venous thrombosis
•	 active or recent arterial thromboembolic disease
•	 prostatic cancer or benign prostatic hyperplasia
•	 porphyria.
CONCLUSIONS
Currently available clinical trials and meta-analyses 
indicate that DHEA supplementation is effective in the 
following cases:
•	 Adrenal insufficiency and chronically treated with ex-
ogenous glucocorticoids
•	 In postmenopausal women with low bone mineral den-
sity and/or osteoporosis
•	 In premenopausal women with sexual disorders and 
low libido
•	 Vaginally in women with vulvovaginal atrophy of meno-
pause or genitourinary syndrome of menopause (GSM)
Currently available clinical trials suggest that DHEA sup-
plementation is probably effective in the some of the 
following cases:
•	 Postmenopausal women with hypoactive sexual dis-
orders
•	 Infertile women with diminished ovarian reserve (DOR)
•	 Women suffer from depression and anxiety
•	 Women with obesity and insulin resistance
Usual daily doses of DHEA that are administrated in clini-
cal trials and regular off-label use are summarized in Table 1. 
In majority of conditions oral dose of 25 mg of DHEA given 
two or three times a day is often implemented.
Commonly used dosage range of DHEA supplementation 
in therapy of diverse medical conditions. Most prevalent dose 
was bolded. Daily doses above 25 mg are usually split into 
Table 1. Usual daily doses of DHEA that are recommended, administrated in clinical trials and regular off-label use
Indication with confirmed effectiveness Daily dose titration range Reference
Adrenal insufficiency and chronically treated with exogenous glucocorticoids 25–50 mg p.o. [33–35]
Postmenopausal women with low bone mineral density and/or osteoporosis 25 mg–50 mg–100 mg p.o. [3, 12]
Premenopausal women with sexual disorders and low libido 75 mg p.o. [29]
Vulvovaginal atrophy/genitourinary syndrome of menopause (GSM) 3.25–23.4 mg p. vag.6.5 mg p. vag. — on market [38–39, 63]
Indication with possible effectiveness Daily dose titration range Reference
Postmenopausal women with hypoactive sexual disorders 10 mg–50 mg–90 mg–300 mg–450 mg p.o. [3, 27–28]
Infertile women with diminished ovarian reserve (DOR) 75 mg p.o. [46–60]
Women with depression and anxiety 30 mg–60 mg–90 mg–450 mg p.o. [22–23]
Women with obesity/insulin resistance 25 mg–50 mg–100 mg p.o. [3]
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2–3 parts. Please note that table summarizes example of doses 
administered in clinical practice that may differ from recom-
mended by manufacturer or are utilized in off-label treatment. 
Administration and dose of every drug should rely on current 
medical knowledge and individual clinical assessment
Recent statement of experts of the Polish Menopause 
and Andropause Society and the Polish Society of Aesthetic 
and Reconstructive Gynecology provides a comprehensive 
literature review that supports the use of intravaginal DHEA 
supplementation. Clinical studies with high level of evidence 
proves that topical treatment is effective, safe and well toler-
ated long-term therapy for vulvovaginal atrophy [63].
In a Cochrane Systemic Review [64] regarding the sup-
plementation of DHEA in peri- and postmenopausal women, 
the authors questioned the effectiveness of DHEA in women, 
but the overall quality of the studies analyzed in this review 
was moderate to low. It was unclear if supplementation of 
DHEA decrease symptoms of menopause since the study 
outcomes were inconsistent and could not be pooled to 
obtain an overall effect due to versatile types of measure-
ment. Insufficient results were available to estimate quality 
of life and menopausal symptoms during DHEA supplemen-
tation as well as, there were inadequate reports accessible 
to compare the effects of DHEA replacement to hormone 
therapy (HT) for quality of life, menopausal symptoms, and 
adverse effects.
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